Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis

Nature Reviews Clinical Oncology

Volumn 7, Issue 7, 2010, Pages 415-420

  Strout, Matthew P ^a   Seropian, Stuart ^a   Berliner, Nancy ^b  

^a YALE CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD68 ANTIGEN; CEFTAZIDIME; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; DOXYCYCLINE; ETOPOSIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ALPHA; LACTATE DEHYDROGENASE; LIVER ENZYME; METHOTREXATE; TRIACYLGLYCEROL; VANCOMYCIN; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; HYPERFERRITINEMIA; HYPOFIBRINOGENEMIA; HYPONATREMIA; IDIOPATHIC DISEASE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LUNG NODULE; MALAISE; OUTCOME ASSESSMENT; PANCYTOPENIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLENOMEGALY; TICK BORNE DISEASE; ALLOTRANSPLANTATION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MULTIMODALITY CANCER THERAPY; REMISSION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77954244065     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.40     Document Type: Article

References (19)

1. Henter, J. I. et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48, 124-131 (2007).
2. Henter, J. I. et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100, 2367-2373 (2002).
3. Arceci, R. J. When T cells and macrophages do not talk: the hemophagocytic syndromes. Curr. Opin. Hematol. 15, 359-367 (2008).
4. Filipovich, A. H. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am. Soc. Hematol. Educ. Program 127-131 (2009)
5. Janka, G. E. Familial and acquired hemophagocytic lymphohistiocytosis. Eur. J. Pediatr. 166, 95-109 (2007).
6. Grunebaum, E., Zhang, J., Dadi, H. & Roifman, C. M. Hemophagocytic lymphohistiocytosis in X-linked severe combined immunodeficiency. Br. J. Hematol. 108, 834-837 (2000).
7. Haliotis, T. et al. Chediak-Higashi gene in humans. I. Impairment of natural-killer function. J. Exp. Med. 151, 1039-1048 (1980).
8. Stepp, S. E. et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286, 1957-1959 (1999).
9. Feldmann, J. et al. Munc13-14 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115, 461-473 (2003).
10. Zur Stadt, U. et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum. Mutat. 27, 62-68 (2006).
11. Busemann, C. et al. Erdheim-Chester disease with hemophagocytosis. Ann. Hematol. 86, 847-849 (2007).
12. Henter, J. I. et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH Study Group of the Histiocyte Society. Med. Pediatr. Oncol. 28, 342-347 (1997).
13. Ostronoff, M. et al. Hemophagocytic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma: successful treatment with high-dose intravenous immunoglobulin. Bone Marrow Transplant. 37, 797-798 (2006).
14. Mahlaoui, N. et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics 120, e622-e628 (2007).
15. Makay, B. et al. Etanercept for therapy-resistant macrophage activation syndrome. Pediatr. Blood Cancer 50, 419-421 (2008).
16. Hu, Y. et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128, 260-270 (2009).
17. Alinari, L. et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 26, 3644-3653 (2007).
18. Horne, A. et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis. Br. J. Hematol. 129, 622-630 (2005).
19. Cooper, N. et al. The use of reduced-intensity stem cell transplantation in hemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplant. 42 (Suppl. 2), S47-S50 (2008).